Biocon in focus as Sandoz’s Enbrel biosimilar delayed

Sandoz's patent trial will start in June 2018 that further delays the launch of the Enbrel biosimilar, which is positive for Biocon.

Apr 03, 2018 09:04 IST India Infoline News Service

Biocon
Biocon is likely to be in focus as its competitor in Enbrel (Etanercept) biosimilar, Sandoz, is likely to see a delayed launch. While Sandoz has already received a USFDA approval for Etanercept biosimilar (Erelzi) in August-2016, a patent row is already going on between Enbrel’s innovator Amgen and biosimilar aspirant Sandoz. The patent trial was first set to take place in 2017 and then in April-2018; it has been further delayed. The trial will now start on June 20, 2018 delaying the first Enbrel biosimilar.

Sandoz had expected to launch Enbrel biosimilar in 2018; however, with the delay in the patent trial, Erelzi launch is now expected to take place in 2019, which will be positive for Biocon.

Enbrel recorded global sales of $8.9bn of which ~$5bn came from the US market in 2017. Any delay in the competition is positive for Biocon/Mylan who are currently conducting clinical trials on Enbrel biosimilar.

Related Story

Open Free Demat Account (Rs699)